DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
G•••••••• B••• I••
Drug Discovery & Developmentgroup grade Aoff every schedule since Sep 30, 2024sponsor unattributed
Also written as: 10; 10/26/2022; 2022; 26; Equity
Nothing material in the last 200 days. Last change: 30 Sep 2024, $31M principal held by 1 lender; matures Jul 2027.
Mark path, consensus per quarter end
100¢ · 101¢ · 98¢ · 96¢ · 97¢Q3 2023 to Q3 2024
Principal held
at least $31.0M
sum of BDC pieces, a lower bound
Fair value
$30.7M
97c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
1 equity pieces beside them
Next maturity
Jul 1, 2027
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Sep 30, 2024
Events
1
dated, non-routine
Lender marks
each lender's own fair value over cost at Sep 30, 2024, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| H••••••• C••••••• I••• | $31M | 97¢ | +1 pts |
Every BDC piece · 2 positions across 1 lenderlargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | term loan first lien S••••• S••••••, M••••••• D••• J••• 2027, P•••• + 3.15%, F•••• rate 7.15%, Cap rate 8.65%, | $31.0M | $30.5M 97c | S+315 bp PIK 2.00% |
| H••••••• C••••••• I••• | equity equity A••••••••• D••• 10/26/2022, Series C••••• S•••• | Not disclosed | $257,000 26c |
Capital structure as the BDCs see it
latest quarter end Sep 30, 2024
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Sep 30, 2024 | at least $31.0M | 97c | S+315 bp PIK 2.00% | Jul 1, 2027 | 1 |
Equity pieces beside the debt: equity ($257,000 fair value, 1 BDC)
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Sep 30, 2024 | 1 | $31.0M | $30.5M | 97c | 1 |
| Jun 30, 2024 | 1 | $30.8M | $30.1M | 96c | 1 |
| Mar 31, 2024 | 1 | $30.7M | $30.4M | 98c | 1 |
| Dec 31, 2023 | 1 | $61.1M | $61.8M | 101c | 2 |
All 8 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Sep 30, 2023 | 1 | $22.9M | $23.1M | 100c | 1 |
| Jun 30, 2023 | 1 | $22.8M | $22.8M | 100c | 1 |
| Mar 31, 2023 | 1 | $22.7M | $21.9M | 97c | 1 |
| Dec 31, 2022 | 1 | $15.1M | $15.1M | 100c | 1 |
What changed
- Facility left every BDC scheduleSep 30, 2024
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- G•••••••• B••derivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it